Letter to the Editor
Low-Dose Azathioprine Effectively Suppresses Clinical and Immunological Manifestations of Generalized Myasthenia
To the Editor:
Azathioprine (AZT) is the treatment of choice for long-term immunosuppression in patients with myasthenia gravis (MG).1,2 There is some evidence that reduction of the standard dosage is ineffective, but some studies even report ineffectivity of the standard AZT dosage for generalized MG.3 We show that low-dose AZT may also effectively suppress acetylcholine-receptor antibodies (AchR-abs) and clinical manifestations of generalized MG.
This content is limited to qualifying members.
If you have an existing account please login now to access this article or view your purchase options.
Create a free account, then purchase this article to download or access it online for 24 hours.
Create a free account, then purchase a subscription to get complete access to all articles for a full year.